Technical Chart Analysis of DRREDDY
DRREDDY is showing signs of recovery after a recent consolidation. The daily chart indicates that price has moved above its shorter-term moving averages (20/50 EMA), which suggests that some buying interest is returning.
Even though the trend had been weak earlier (lower highs, lower lows), the stock managed to form a higher low recently, showing that downside momentum may be easing.
Key resistance lies around the ₹1,320-₹1,340 zone; sustaining above this area would be a positive sign for further upside.
Support zones are forming in the ₹1,260-₹1,240 region; a fall below these could put pressure on the recovery.
Indicators: RSI is moderately positive, MACD has shown signs of flattening and possibly preparing for a crossover, but is not yet strongly bullish. Volume confirmation in coming sessions will be important to validate the move.
Fundamental View
Dr. Reddy’s is a major Indian pharma company, with well-diversified operations in generics, branded drugs, biosimilars, and research pipelines.
It has a strong global presence and multiple manufacturing/export units, contributing to global API and finished dosage supplies.
The company has been focusing on launching novel molecules, entering new therapeutic categories, and expanding its branded portfolio.
Financially, Dr. Reddy’s has had periods of margin pressure due to regulatory compliance, raw material cost fluctuations, and competition, but its product launches and pipeline updates offer levers for growth.